The prostate gland is the male organ commonly afflicted with either benign or malignant neoplasm. Adenocarcinoma of the prostate is the most common cancer diagnosed and the second leading cause of cancer death among males in the United States. 1 Benign prostatic hyperplasia (BPH) is the most common benign tumor in men, and its incidence is age related. Although BPH is not a fatal disease, it can induce bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS). So, BPH poses a significant health problem in the industrialized Western world. 2, 3 Although BPH and prostatic cancer may be unrelated etiologically, they frequently occur together. So, it is important to detect concomitant cancer in BPH patients. It is a dilemma to clinician when facing with the treatment options of BPH that is present along with prostate adenocarcinoma. The best way to do this currently is serum prostate-specific antigen (PSA) determination, digital rectal examination (DRE), and transrectal ultrasonography (TRUS). However, DRE and TRUS cannot detect the 10-20% of patients who have prostatic cancer within the transition zone. PSA may be useful to detect such patients but it cannot detect all cancers. 4 Any developed treatment modality of BPH can relieve BOO, but cannot treat concomitant prostatic cancer. If new treatment modality of BPH can treat concomitant prostatic adenocarcinoma, it can be a fascinating tool for clinician to manage patients with BPH. Theoretically targeting gene therapy of prostatic epithelial cells can do this and it will be a powerful treatment modality of BPH. 5, 6 . In order to develop a novel targeting gene therapeutic modality for the treatment of BPH, we investigate the properties of PSA promoter-based suicide gene therapy utilizing herpes simplex virus thymidine kinase (HSV-TK) toxic gene with prodrug in a canine model. It can induce apoptosis in PSA-secreting epithelial cells of prostate origin with minimal systemic toxicity. Here, we report in vivo data supporting the efficacy of PSA promoter-based targeting gene therapeutic modality. The final goal of this study is to develop effective treatment modality of both clinical BPH and concomitant prostatic adenocarcinoma simultaneously.
Experiment was performed in three different groups. In group I, we performed only one time injection of Ad-PSA-HSV-TK with 10 mg per kilogram of body weight acyclovir. In group II, we performed two times injections of Ad-PSA-HSV-TK with 20 mg per kilogram of body weight acyclovir. In group III, two times of injection of Ad-PSA-HSV-TK were performed without acyclovir ( Table 1) . The Ad-PSA-HSV-TK was injected into the left half of the canine prostate. In the prostates of group II animals, the left lobe showed segmental lesions characterized by marked atrophy of ducts and acini with dense infiltration of lymphocytes and plasma cells. Its distribution was sharply segmental along the ramification of ductal branch. The stroma showed heavy infiltration of lymphocytes and plasma cells and infiltrate extended into the ductal and acinar epithelium. The number of acini was decreased. Ducts and acini collapsed into a stellate or rounded outline with reduced luminal area and intraluminal ridges were lost. And, cystically dilated lumen was also found. The secretory cells of acinar epithelium were decreased in number. The volume of cytoplasm of secretory cells was reduced and loss of cytoplasmic granularity was noted. The above atrophic changes of ducts and acini were most prominent in the center of the lesions (Figure 1 ). Apoptotic bodies, composed of intensely eosinophilic cytoplasm with dense nuclear chromatin fragment, were more frequently found in the left lobe, especially on secretory cells in the , GlaxoWellcome Greenford, UK) with amount of 10 mg/kg body weight intravenously from day 0 to day 14 and the adenoviral vectors were delivered to the animals on day 1. The group II included three dogs. The animals of group II received daily ACV with an amount of 20 mg/kg body weight intravenously from day 0 to day 14 and the adnoviral vectors were delivered on days 1 and 7. In group III, two dogs, the adnoviral vectors were delivered on days 1 and 7 without ACV. The adenoviral vectors were diluted in 500 ml of normal saline and delivered to one anesthetized dog by intraprostatic injection. A laparotomy was performed and 5 Â 10 9 PFUs of Ad-PSA-HSV-TK were directly injected into left half of the prostate and contralateral right half was treated with normal saline and used as control. On 56th experimental day, the dogs were euthanized, and prostate and vital organs including liver, heart, lung, brain and kidney were obtained at necropsy. Suicide gene therapy in canine prostate HS Park et al periphery of the lesions and lymphocytes in the center of the lesions, and remarkable histologic alterations were not found in the right lobe. In prostates of group I animals, we could not detect any remarkable histologic difference between both the lobes. Some glandular atrophy is also identified in group III animals, but the changes are much less than group II (Figure 2 ). On immunohistochemical stain for PSA, cytoplasm of secretory cells revealed immunoreactivity for PSA. In prostates of group II animals, lesions of the left lobe showed a decreased number of PSA-positive secretory cells compared to the control right lobe (Figure 3) . Especially, complete loss of PSA-positive secretory cells was noted in the center of the lesions. In prostates of groups I and III animals, there was no remarkable difference in the number of PSA-positive secretory cells between both the lobes ( Figure 2) .
We also studied apoptosis using the TUNEL method. In prostates of group II animals, apoptosis was more frequently found in the treated left lobe of the prostate than the control right lobe (Figure 4) . Apoptosis of epithelial cells was most frequent in the periphery of the lesions. In the center of the lesions, apoptosis of infiltrated lymphocytes was prominent. In prostates of groups I and III animals, there was no significant difference in the number of apoptotic cells between both the lobes (Figure 3) .
The suicide gene used in the present system is the most important one of the negative selective markers, whose protein products convert a prodrug into its toxic from. The HSV-TK gene is widely used as a therapeutic gene in the suicide gene therapy model of prostate and other cancers, and transfection with the HSV-TK gene makes the target cells susceptible to the prodrug, acyclovir. Ayclovir is a nucleoside analogue that can be phosphorylated by the HSV-TK therapeutic gene into the monophosphated form. And then normal cellular enzymes can diphosphorylate and triphosphorylate the monophosphorylate form into the toxic products. The toxic products are capable of blocking host cell DNA synthesis by inhibiting DNA polymerase, and ultimately cause the cell death. [7] [8] [9] [10] The genetic vectors can deliver the therapeutic gene to target tissues. Several viral or nonviral vectors are suggested for gene transfer, and the adenovirus vectors are more preferred, because of the high yields of virus obtainable compared to retroviruses and because high infection efficiency is possible with adenovirus. In addition, adenoviruses do not integrate into the host genome, lessening concerns about insertional mutagen- esis. This viral vector delivers the therapeutic gene within the Ad genome, which typically comprises 36 kb of viral sequences and this vector has the capacity to infect cells that are not dividing and deliver the doublestranded genome to the nucleus in episomal form. [11] [12] [13] [14] In the present study of gene therapy for BPH, we chose the recombinant replication-deficient adenovirus vector to transfer the HSV-TK suicide gene. For the BPH study, we use the beagle dog as an experimental animal because the canine prostate most closely mimics the human prostate. Moreover, BPH and adenocarcinoma develop in the canine prostate during aging. Therefore, the study conducted in the canine prostate may reflect the more natural situations as to the human prostate environment compared with xenograft human prostate tumors or prostates from other animals. 15, 16 A more developed model of suicide gene therapy is the targeted expression of the therapeutic gene. Several tissue-or disease-specific promoters are used in targeting gene therapy such as tyrosine promoter for the treatment of melanoma, albumin promoter for the treatment of hepatoma, and PSA promoter for the treatment of the prostatic cancers. 17, 18 The targeting expression of therapeutic gene increases the specificity and safety of gene therapy. In the previous studies of suicide gene therapy in the canine prostate, following the intraprostatic injection of adenoviral vectors, adenovirus may be disseminated to the many other organs such as the bladder, vas deferens, heart, and liver by direct extension, reflux from the ejaculatory ducts, or hematogenous spread. If adenovirus vector with a universal promoter such as the rous sarcoma virus (RSV) was used, the transgenic gene expression was also identified in prostate and other organs. 16, 19, 20 The ability to restrict transgenic gene expression by designing prostate-specific viral vectors may theoretically minimize the potential systemic toxicity. PSA is a 34 kDa chymotrypsin-like serine protease that is secreted exclusively by normal and cancerous epithelial cells lining both the prostatic acici and ducts. 21 It can be used as a promoter for prostate-specific transgenic gene expression. However, there were some differences of PSA production in benign and malignant prostatic epithelial cells between humans and dogs. In McEntee et al's, 22 study, immunohistochemical staining of dog prostate revealed that normal and hyperplastic canine prostatic epithelium was strongly positive with PSA. However, only two of 31 dog adenocarcinomas were positive with PSA. 22 These results contrast with those in human studies in which PSA is expressed in normal and neoplastic epithlium with comparable intensity in all but the most anaplastic tumors.
It has been reported that the 620 bp PSA promoter isolated from a patient with prostatic cancer has the prostate-specific expression of reporter gene. 23 However, the 620 bp PSA promoter has reduced activity as compared with universal viral promoters. The 620 bp PSA promoter has at least a 10-fold lower level of activity than did the RSV promoter. 20 Recently, the PSA promoter with a long upstream sequence of 5937 bp has been Figure 3 Immunohistochemical staining of canine prostatic tissues using PSA monoclonal antibody: immunohistochemical staining for PSA was performed using rabbit monoclonal antibody to human prostate-specific antigen (DAKO, Carpinteria, CA, USA) and DAKO Labelled StreptavidineBiotin s 2 System (DAKO, Carpinteria, CA, USA). Sections of 4 mm thickness were dewaxed with xylene and then heated in a microwave oven for 20 min to retrieve antigens. Endogenous peroxidase was blocked using 3% hydrogen peroxide solution. The sections were incubated with primary antibody for 20 min at 371C. After washing, goat anti-rabbit and anti-mouse immunoglobulins were applied for 7 min at 371C, and then followed by incubation with streptavidin-horseradish for 7 min at 371C. The sections were developed in 3, shown to have a superior activity over the shortsequence PSA promoter; and the long PSA promoter preserves tissue-specific expression. The strength of the long PSA promoter can be modulated in PSA-secreting cells by androgen to a level comparable to that expressed by universal CMV promoter-mediated gene expression. 24 In this study, we used the long PSA promoter with 5937 bp for prostate-specific genetic expression and could achieve adequate selective ablation of PSA-secreting epithelial cells in the canine prostate. Although only the transfected cells can express the therapeutic HSV-TK suicide gene, apoptosis can occur not only in the transfected cells but also those in close proximity, a phenomenon called the 'bystander effect'. This phenomenon is well described and contribute remarkable efficacy in tumor destruction as demonstrated in vitro and in vivo. An important feature of this effect is that when 10% of cells in a tumor contained HSV-TK suicide gene, the entire population of tumor cells could be killed through the phagocytosis of apoptotic bodies by the nearby tumor cells, and transfer of phosphorylated acyclovir through gap junctions. 25, 26 Recently, there have been reports that soluble cytokines, for example, TNF or IL, and changes in tumor environment may generate an antitumor immune response that could involve the bystander effect of suicide gene therapy. 8, 27 Pathologic examination of canine prostates after Ad-PSA-HSV-TK suicide gene therapy revealed the characteristic features that may be because of the bystander effect. These features are well-marginated segmental lesions characterized by marked atrophy of ducts and acini with dense infiltration of lymphocytes and plasma cells. The major excretory ducts of prostate are located in the central area, they branch to several small ducts and connect to many acni of peripheral area. If apoptosis spreads through ductal and acinar system of the prostate, it can make segmental lesion between periurethral and peripheral areas. The periurethral area of the prostate is the convergence site of ductal and acinal systems. So theoretically transurethral in situ genetic vector delivery is more effective and maximizes the bystander effect than transrectal route. This therapeutic trial can be developed as a novel gene therapy for the treatment of human BPH.
There are several merits in gene therapy of the prostate. First, it is easy to access by transurethral or transrectal route. So, in situ gene therapy is easier than other organs. 10, 28 Second, several proteins are known to be expressed in a tissue-specific manner, including PSA, human glandular kallikrein 2 (hKLK2), and prostate- Figure 4 Detection of apoptosis in canine prostatic tissues by TUNEL method: the detection of apoptosis by the TUNEL (terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-uridine triphosphate (dUTP)-biotin nick end labeling) method was carried out using ApopTag s Peroxidase Kit (Intergen Company, Purchase, NY, USA) according to the method of Gavrieli. Briefly, 4 mm thick sections were dewaxed with xylene and treated with proteinase K (20 mg/ml) at room temperature for 15 min. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide solution for 5 min. Each section was incubated with 75 ml of equilibration buffer for 10 min. Working strength terminal deoxynucleotidyl transferase (TdT) enzyme was applied in a humidified chamber at 371C for 70 min. The sections in a jar containing working strength stop/wash buffer were agitated for 15 s, and then incubated for 10 min at room temperature. Antidigoxigenin peroxidase conjugate was applied for 30 min in a humidified chamber at room temperature. After washing in phosphatebuffered saline, enough DAB solution was applied to cover completely the specimen and staining was performed for 5 min at room temperature. After washing in distilled water, sections were counterstained in 0.5% methyl green for 20 min. Section from palatine tonsil was used as a positive control. Apoptosis of epithelial cells are much increased in treated prostatic gland (a) than control (b). (a) Ad-PSA-HSV-TK plus acyclovir, Â 400; (b) acyclovir only, Â 400.
Suicide gene therapy in canine prostate HS Park et al specific membrane antigen (PSMA). So, the prostate is a suitable candidate for tissue-specific targeted expression of toxic gene therapy using tissue-specific promoters. Third, in the prostate, both normal and malignant cells have been shown to have abundant connexin proteins. The connexin proteins make up cylindrical particles in the cell membrane. These particles, which are tiny water-filled channels, are the key to gap junction function. With the likelihood of gap junction playing a significant role in the local aspect of the bystander effect, prostate gene therapy can be potentiated by methods to increase connexin expression and gap junction formation. 29, 30 In conclusion, we suggested that the prostate is the ideal organ for in situ gene therapy and organ-specific targeting gene therapy is easier than other human organs. The long PSA promoter-based in situ suicide gene therapy, using HSV-TK therapeutic gene, can achieve selective ablation of PSA-secreting epithelial cells in the canine prostate. Gene therapy using recombinant adenovirus containing PSA-HSV-TK gene expression cassette may be an effective therapeutic modality for the treatment of both BPH and concomitant adenocarcinoma.
